Paratek Pharmaceuticals (PRTK): Catalysts Ahead - Guggenheim
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Guggenheim analyst, Louise Chen, reiterated her Buy rating on shares of Paratek Pharmaceuticals (NASDAQ: PRTK) and noted catalysts ahead for the company. PRTK plans to dose the first patient in its oral-only skin study of omadacycline in August. The company recently received affirmation from the FDA on the design of its Phase 3 oral-only ABSSSI study. She expects this study to report top-line data in 2Q17. She estimates omadacycline peak sales of $1B+, which is significantly higher than Street expectations of $100MM+. Unlike other new antibiotics in development, omadacycline can be used in the community in addition to the hospital setting, and accelerated approval of the oral-only indication could mean peak sales being achieved sooner than expected.
Shares of Paratek Pharmaceuticals closed at $13.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Jefferies Cuts Price Target on Waters Corp. (WAT) Following Revenue Miss
- Apple (AAPL) PT Raised to $135 at Brean Capital
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesLouise Chen, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!